Centralized Pan-european Survey on the Undertreatment of Hypercholesterolemia (CEPHEUS)

M.P. Hermans; W. Van Mieghem; G. Vandenhoven; E. Vissers

this issue

previous article in this issue

next article in this issue

Document Details :

Title: Centralized Pan-european Survey on the Undertreatment of Hypercholesterolemia (CEPHEUS)
Author(s): M.P. Hermans , W. Van Mieghem , G. Vandenhoven , E. Vissers
Journal: Acta Cardiologica
Volume: 64 Issue: 2 Date: 2009
Pages: 177-185
DOI: 10.2143/AC.64.2.2035341

Abstract :
The CEntralized Pan-European survey on tHE Under-treatment of hypercholeSterolaemia (CEPHEUS) was initiated to quantify the degree of under-treatment of hypercholesterolaemia in Europe. Its primary objective was to establish the proportion of treated patients reaching the LDL-C goals according to the Third Joint European Task Force guidelines. Secondary objectives targeted subgroups of primary or secondary prevention patients and those with a metabolic syndrome. Furthermore, CEPHEUS also aimed at the identification of determinants for under-treatment.
Among the patients available for evaluation in Belgium (n = 6276), 58.5% reached LDL-C goals as recommended by the 2003 European guidelines, 59.8% in primary prevention, 55.8% in secondary prevention, and 55.8% of those with a metabolic syndrome. The majority of patients (82.5%) was treated with statins.
The univariate significant (P < 0.10) predictors of attaining LDL-C goal were the following: (a) non-smoker, (b) no history of PAD or CAD, (c) absence of metabolic syndrome, (d) lower CV risk category, (e) absence of patient’s concerns about treatment changes, (f) no withdrawal of lipid-lowering therapy when on target, (g) optimal treatment adherence, (h) no patient’s frustrations, (i) lipidmonitoring frequency, (j) physician being a specialist and (k) physicians finding it stressful to get patients on target.
In an adjusted multi-level model, achievement of the LDL-C goals was significantly associated with: (a) type of lipid-lowering therapy, (b) risk category the patient fell into, (c) LDL-C level before initiating treatment, (d) patient’s feelings about the treatment, (e) patient’s acknowledgement about current cholesterol level and (f) self-reported drug compliance.